医学
安慰剂
内科学
耐受性
临床终点
人口
红斑狼疮
置信区间
不利影响
随机对照试验
免疫学
病理
抗体
环境卫生
替代医学
作者
Yoshiya Tanaka,Tatsuya Atsumi,Masato Okada,Tomoya Miyamura,Tomonori Ishii,Susumu Nishiyama,Ryutaro Matsumura,Nobuya Hayashi,Gabriel Abreu,Raj Tummala,Eric Morand,Tsutomu Takeuchi
摘要
ABSTRACT Objectives Evaluate the efficacy and safety of anifrolumab in the subpopulation of Japanese patients with systemic lupus erythematosus (SLE) in phase 3 TULIP-2 trial. Methods TULIP-2 was a 52-week randomized placebo-controlled trial (N = 362) that evaluated efficacy and safety of anifrolumab 300 mg IV every 4 weeks vs. placebo in patients with moderate to severe SLE who were receiving standard therapy. We performed a post hoc analysis of the primary and key secondary endpoints, and safety, of TULIP-2 in the Japanese subpopulation. Results In the Japanese subpopulation (anifrolumab, n = 24; placebo, n = 19), the proportion of patients who achieved a British Isles Lupus Assessment Group–based Composite Lupus Assessment response at Week 52 (primary endpoint) was greater in the anifrolumab group vs. placebo [50.0% (12/24) vs. 15.8% (3/19); treatment difference: 34.2%, 95% confidence interval 6.9, 61.5; nominal p = .014]. Improvement in skin activity and flare rates (key secondary endpoints) were favourable for anifrolumab vs. placebo. Consistent with the overall population, anifrolumab had an acceptable safety and tolerability profile. Conclusions The efficacy and safety of anifrolumab 300 mg in Japanese patients with SLE was consistent with the demonstrated clinical profile of anifrolumab for the overall TULIP-2 population.
科研通智能强力驱动
Strongly Powered by AbleSci AI